Glenmark Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 1
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Glenmark Pharmaceuticals Ltd. from all sources in a single place.

Load latest

Glenmark Pharmaceuticals Ltd.

04 Aug 2025

2132.50

0.23%

SAST

Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window

BSE India

The trading window has been closed from June 30, 2025 to August 16, 2025 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2025

pdf

Glenmark Pharmaceuticals Ltd.

04 Aug 2025

2132.50

0.23%

Board Meeting

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving The Financial Results …

BSE India

Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2025.

pdf

Glenmark Pharmaceuticals Ltd.

01 Aug 2025

2132.50

0.23%

AGM

Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

BSE India

Voting result as required under Regulation 44(3) of SEBI Listing Regulations and Scrutinizer''s Report is enclosed.

pdf

Glenmark Pharmaceuticals Ltd.

25 Jul 2025

2132.50

0.23%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Advertisement for transfer of Equity Shares to IEPF Authority.

pdf

Glenmark Pharmaceuticals Ltd.

23 Jul 2025

2132.50

0.23%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Kindly find enclosed rating rationale issued by India Ratings and Research for your reference.

pdf

Glenmark Pharmaceuticals Ltd.

23 Jul 2025

2132.50

0.23%

Earnings Call

Glenmark Pharmaceuticals Ltd - 532296 - Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day …

BSE India

Audio recording of Investor Day 2025 held on 16th July, 2025.

pdf

Glenmark Pharmaceuticals Ltd.

18 Jul 2025

2132.50

0.23%

ISB 2001 deal well-done; valuation defies uncertainties ahead

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) subsidiary Ichnos Glenmark Innovation (IGI) has out-licensed its oncology asset ISB 2001 to Abbvie in a deal valued at USD 1.925bn, including USD 700mn upfront, USD 1.225bn in milestones and tiered doubledigit royalty on net sales.

Glenmark Pharmaceuticals Ltd. has gained 30.40% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

17 Jul 2025

2132.50

0.23%

Glenmark Pharma Will Turn Cash Positive With AbbVie's Licensing Deal: SP

NDTV Profit

Glenmark, through wholly-owned subsidiary IGI Therapeutics SA, announced an exclusive licensing agreement with AbbVie for ISB 2001.

Glenmark Pharmaceuticals Ltd. has gained 30.40% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

12 Jul 2025, 09:29PM

2132.50

0.23%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Communication from U.S. FDA

pdf

Glenmark Pharmaceuticals Ltd.

12 Jul 2025, 07:53AM

2132.50

0.23%

Glenmark surges 20% after major drug licensing deal with AbbVie

Economic Times

Glenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a drug targeting oncology and autoimmune diseases. Glenmark will receive $700 million upfront. Potential milestone payments could reach $1.2 billion. Future sales will also generate revenue for Glenmark. Analysts predict a positive re-rating of the stock due to this deal.

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf